宫瘤宁胶囊对气滞血瘀证子宫肌瘤瘤体的抑制作用

发布时间：2018-03-27 17:48

本文选题：子宫肌瘤　切入点：宫瘤宁胶囊　出处：《中国实验方剂学杂志》2016年24期

【摘要】：目的:评价宫瘤宁胶囊联合米非司酮治疗子宫肌瘤气滞血瘀证的临床疗效及对血清中血管内皮生长因子(VEGF),基质金属蛋白酶9(MMP-9),转移生长因子-β1(TGF-β1),表皮生长因子(EGF)表达的影响。方法:将146例患者采用随机按数字表法分为对照组和联合组各73例。对照组采用米非司酮片,月经第1天开始,25 mg·d~(-1),晨服。联合组在对照组治疗的基础上加用宫瘤宁胶囊,6粒/次,3次/d。两组疗程均为3个月。采用彩超测量治疗前后肌瘤和子宫大小;进行治疗前后气滞血瘀证评分;检测治疗前后促卵泡刺激素(FSH),促黄体生成素(LH),雌二醇(E2)和孕激素(P)水平;检测治疗前后VEGF,MMP-9,TGF-β1和EGF水平;随访6个月,记录复发情况。结果:联合组临床疗效总有效率为92.31%,高于对照组的78.13%(P0.05);治疗后联合组肌瘤和子宫体积小于对照组,气滞血瘀证评分低于对照组(P0.01);治疗后联合组E2,P,FSH,LH水平均低于对照组(P0.01);治疗后联合组VEGF,MMP-9,TGF-β1和EGF水平均低于对照组(P0.01);联合组复发率24.62%,低于对照组的48.44%(P0.01)。结论:宫瘤宁胶囊联合米非司酮治疗气滞血瘀型子宫肌瘤在缩小瘤体,改善症状,提高临床疗效,降低复发率方面均优于单纯的米非司酮治疗,其作用机制可能与下调性激素水平,调节VEGF,MMP-9,TGF-β1和EGF等因子的表达有关。
[Abstract]:Objective: to evaluate the clinical efficacy of Gongyuning capsule combined with mifepristone in the treatment of hysteromyoma with blood stasis syndrome and the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase 9 (MMP-9), metastatic growth factor- 尾 1 (TGF- 尾 1) and epidermal growth factor (EGF) in the serum of uterine leiomyoma with Qi stagnation and blood stasis syndrome. Methods: 146 patients were randomly divided into control group (n = 73) and combined group (n = 73). On the first day of menstruation, 25 mg / d ~ (-1) was taken in the morning. On the basis of the treatment of the control group, the combined group was given 6 capsules of Gongyunning capsule / 3 times / d. The course of treatment was 3 months. The size of myoma and uterus was measured by color Doppler ultrasound before and after treatment. The levels of follicle stimulating hormone (FSH), luteinizing hormone (LHN), estradiol (E2) and progesterone (P) were measured before and after treatment, and the levels of VEGF, MMP-9, TGF- 尾 1 and EGF were measured before and after treatment. Results: the total effective rate of the combined group was 92.31, which was higher than that of the control group (78.13%, P 0.05), and the volume of myoma and uterus in the combined group was smaller than that in the control group. The scores of qi stagnation and blood stasis syndrome were lower than that of the control group (P 0.01); after treatment, the levels of E _ 2 / P _ (+) FSH / LH in the combined group were lower than those in the control group (P _ (0.01)); after treatment, the levels of VEGFU, MMP-9, TGF- 尾 _ 1 and EGF in the combined group were lower than those in the control group (P _ (0.01)); the recurrence rate in the combined group was 24.62, which was lower than that in the control group (P _ (0.01)). The combination of mifepristone in the treatment of hysteromyoma of qi stagnation and blood stasis is reducing the body of uterine leiomyoma. Improvement of symptoms, improvement of clinical efficacy and reduction of recurrence rate were better than those of mifepristone alone, and the mechanism might be related to the down-regulation of the level of sex hormones and the regulation of the expression of VEGF-尾 1 and EGF.
【作者单位】：邢台市人民医院;
【基金】：邢台市科技局医学卫生基金(2014WS0528)
【分类号】：R737.33

【相似文献】